INSTANT STREAMING COURSE
Share:

Navigating the FDA's Guidelines on Off-Label Promotions

This course equips regulated industry professionals to assess off-label communication practices against current FDA expectations, reducing exposure to untitled letters, inconsistent publication handling, and preventable promotional compliance failures across pharmaceutical and medical device activities. This Course is designed for professionals responsible for regulated product communications, scientific publications, compliance oversight, and promotional practices.

REGISTER FOR THE COURSE

US $190 per learner

30-Days Unlimited Streaming Access

/* Hide default + / - icon */ .accordion-toggle-icon { opacity: 0; } /* Add circle instead */ .accordion-header::after { content: "○"; font-size: 18px; margin-left: auto; transition: 0.2s ease; } /* When open → filled circle */ .accordion-item.active .accordion-header::after { content: "●"; } /* Hide default + / - icon */ .accordion-toggle-icon { opacity: 0; } /* Add circle instead */ .accordion-header::after { content: "○"; font-size: 18px; margin-left: auto; transition: 0.2s ease; } /* When open → filled circle */ .accordion-item.active .accordion-header::after { content: "●"; } .accordion-header::after { content: "◯"; font-size: 18px; transition: transform 0.25s ease; } .accordion-item.active .accordion-header::after { transform: rotate(90deg); }

REGISTER FOR THE COURSE

To Get 30-Day Access to ONLY this Course 

US $190 per learner
  • This course is Included in Subscription Pack
Subscription include access to entire Learning Library
/* Hide default + / - icon */ .accordion-toggle-icon { opacity: 0; } /* Add circle instead */ .accordion-header::after { content: "○"; font-size: 18px; margin-left: auto; transition: 0.2s ease; } /* When open → filled circle */ .accordion-item.active .accordion-header::after { content: "●"; } /* Hide default + / - icon */ .accordion-toggle-icon { opacity: 0; } /* Add circle instead */ .accordion-header::after { content: "○"; font-size: 18px; margin-left: auto; transition: 0.2s ease; } /* When open → filled circle */ .accordion-item.active .accordion-header::after { content: "●"; } .accordion-header::after { content: "◯"; font-size: 18px; transition: transform 0.25s ease; } .accordion-item.active .accordion-header::after { transform: rotate(90deg); }
  • Faculty
    Kelly Thomas
  • Duration
    90 Minutes
  • Course ID
    TF3209
  • Ask the Expert
    Included
  • Presentation Handout
    & Templates
  • Assessment
    & Certification Included

About the Course

FDA oversight of prescription drug and medical device labeling and advertising continues to shape how manufacturers communicate scientific and medical information to healthcare professionals. Distributing publications that reference unapproved uses of approved or cleared products can create regulatory exposure when communication practices fall outside current FDA expectations. Organizations involved in promotional review, medical affairs, and scientific dissemination must distinguish between permissible scientific exchange and promotional activity that may trigger agency scrutiny.


The course addresses the FDA’s current policy on distributing scientific and medical references containing off-label information, along with applicable statutes, regulatory requirements, monitoring activities, and untitled letter analysis. Attention is also given to publication practices, avoidable compliance mistakes, and internal measures that support consistent communication standards. The material is structured for organizations seeking practical direction on reducing enforcement risk while maintaining appropriate scientific and medical communications involving approved drugs and cleared medical devices.

  • Interpreting FDA Expectations for Off-Label Communications:

    Participants gain a clearer framework for evaluating scientific and medical publications that reference unapproved uses of approved or cleared products. The course connects FDA policy, regulatory requirements, and surveillance activity to day-to-day communication decisions, helping organizations reduce inconsistent review practices that can contribute to untitled letters or additional regulatory attention.

  • Strengthening Publication and Promotional Review Practices:

    The material provides practical direction for identifying avoidable compliance mistakes associated with off-label promotion and scientific dissemination. Coverage of publication practices, monitoring activities, and enforcement considerations supports more consistent internal review processes during promotional planning, medical communication review, and interactions involving healthcare professionals using FDA approved or cleared products.

Key Areas Covered

  • Applicable statutes and regulatory requirements governing off-label promotion
  • FDA jurisdiction over prescription drug and medical device labeling and advertising
  • Communication standards for scientific and medical publications discussing unapproved uses
  • FDA monitoring and surveillance activities related to promotional practices
  • FDA current policy on dissemination of off-label scientific references
  • Good medical and scientific publication practices for approved and cleared products
  • Analysis of FDA untitled letters and recurring compliance deficiencies
  • Preventive measures for reducing avoidable promotional and publication-related mistakes

Who Must Attend

  • QA/QC Departments
  • Research and Development Teams
  • Clinical Affairs Professionals
  • Regulatory Affairs Departments
  • Compliance Professionals
  • Contractors/Subcontractors

Quality training, expert insights, and answers that matter. Know your Expert

KELLY THOMAS

Ms. Thomas brings more than two decades of pharmaceutical and medical device industry experience involving quality systems, validation, and regulated manufacturing operations. Her background includes process and product validation, facilities validation, computerized systems validation, and 21 CFR Part 11 activities. She has managed complex projects using risk-based and Lean approaches within regulated environments, providing practical perspective on operational controls, documentation practices, and compliance considerations relevant to FDA oversight and regulated communications.

If you would like to request a Proforma invoice to sign up for this course. please click here

Commonly Asked Questions About This Subject

The following questions address practical regulatory, compliance, validation, quality, operational, and inspection-related considerations commonly associated with this subject.

How should organizations document decisions involving scientific communications that may reference off-label information?

Documentation should explain the reasoning behind the communication, not simply record that it was reviewed. During regulatory reviews or internal investigations, decision makers are often asked to demonstrate why a communication was considered appropriate and what evidence supported that conclusion.


Review records should identify the communication objective, intended audience, supporting scientific evidence, applicable internal review criteria, and the individuals responsible for the final decision. Documentation that only contains approval signatures provides little context if questions arise months or years later.


Inspectors frequently compare review records with the final distributed materials and related communications. Differences between documented intent and actual execution often receive greater scrutiny than the underlying scientific content itself. Incomplete records also make it difficult to demonstrate that similar communications were evaluated consistently.


A well documented review process provides evidence that decisions were deliberate, supported, and consistently applied. Clear documentation strengthens regulatory defensibility by preserving the rationale behind communication decisions rather than relying on retrospective explanations.

When should scientific communication decisions require formal governance rather than routine promotional review?

Some communication decisions carry broader regulatory implications and should receive oversight beyond routine promotional review. Communications involving emerging evidence, significant business impact, novel dissemination approaches, or unresolved interpretation questions often benefit from formal governance before distribution.


Governance provides an opportunity to evaluate issues from multiple perspectives, including regulatory affairs, medical affairs, legal, compliance, and commercial leadership. Cross functional review helps identify concerns that may not be apparent when decisions remain within a single department.


Reviewers often examine whether governance processes were applied consistently across comparable situations. Similar communications receiving different levels of review without documented justification can weaken confidence in the organization's oversight framework.


Formal governance also creates a documented record showing how complex decisions were evaluated, who participated, and why a particular approach was selected. This evidence is often valuable when defending communication practices during inspections, audits, or internal investigations.

How should organizations establish risk based review criteria for different types of scientific communications?

Communication review criteria should reflect the regulatory and business risk associated with each type of scientific communication rather than applying identical review expectations across every situation. A structured, risk based approach helps ensure that higher risk communications receive greater scrutiny while routine activities follow an efficient and consistent review pathway.


Review criteria should consider factors such as the intended audience, scientific complexity, communication channel, novelty of the information, potential regulatory sensitivity, and the likelihood that the material could influence clinical decision making. Documenting how these factors affect review requirements strengthens consistency across similar communications.


Inspection concerns often arise when comparable communications receive different levels of review without documented justification. Inconsistent review pathways make it difficult to demonstrate that governance decisions are objective and based on established criteria rather than individual judgment.


Organizations that define review thresholds before communications are developed are generally better positioned to defend their decision making. A documented framework creates consistent expectations, reduces unnecessary rework, and provides evidence that review resources are focused where regulatory risk is greatest.

What governance weakness becomes most visible after a significant post-market safety event?

A governance concern frequently emerges when responsibility for surveillance activities is fragmented across departments. Complaint handling, vigilance, quality, regulatory affairs, medical review, risk management, and data analytics may all contribute information without clear ownership of final decisions.


Following a significant event, investigators often reconstruct who reviewed specific information, who had authority to escalate concerns, who evaluated trends, and who decided that no action was necessary. Delays, conflicting interpretations, and undocumented handoffs quickly become visible.


Inspection findings often stem less from missed data and more from uncertainty regarding accountability. Information existed. Signals were observed. Questions were raised. What cannot be clearly demonstrated is who owned the decision process and how conclusions were reached.


Evidence of strong governance includes documented decision authorities, escalation criteria, cross-functional review expectations, meeting records, challenge discussions, and clear ownership of surveillance outcomes. When accountability remains visible throughout the record, organizations are generally in a stronger position to explain and defend their actions after a safety concern emerges.

Ready to Strengthen Your Team? Let’s Build Your Training Plan.

Whether you’re looking for a single onsite workshop or a multi-team training series, we’ll help you design a program that fits your goals, timelines, and operational reality.

Your team deserves the clarity.
Your organization deserves the confidence.

Upcoming Courses

Your TalkFDA Webinar Experience

When you reserve your seat, everything is organized for you — from access to certification from one place.

1. Confirmation

You receive a confirmation email and your course appears instantly in your TalkFDA dashboard.

2. Your Course Hub
Your TalkFDA course page becomes your central hub where you can watch the course, access materials, and manage your learning.

3. Access course materials
The presentation handout and other materials can be downloaded inside the Course Player. You could use Discussion feature there to ask your questions.

4. Watch The Streaming and Complete your Course
The course playback will be available on the same course page. You could pause and continue or you can revisit important sections.
5. Earn Your Certificate
Complete the course and your certificate is unlocked automatically in your learning history.

The challenge with training is rarely signing up. It’s what happens afterward, when access, materials, & certification aren’t accessible from one place.
With TalkFDA Courses, Everything you need Live in One Place.
Simple. Organized. Professional.
Go ahead and Take the Course with confidence.

Our students love us ❤️

“Content was put together well. Didn’t feel like random slides. One thing actually led to the next.”

Manager, Quality Assurance

“Material was easy to revisit afterward. Helped our team align on key points internally.”

Lab Manager, Quality Control

“Would consider similar sessions again. Format worked for us.”


Director, Regulatory Affairs

People who took this Course, also viewed